Skip to main content

Advertisement

SpringerLink
Log in

Immunotherapy‑based combinations versus standard first‑line and hypothyroidism risk

  • Correspondence
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

The Original Article was published on 19 January 2020

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Buti S, Petrelli F, Ghidini A, Vavassori I, Maestroni U, Bersanelli M. Immunotherapy-based combinations versus standard first-line treatment for metastatic clear cell renal cell carcinoma: a systematic review and meta-analysis. Clin Transl Oncol. 2020;2020:1–7.

    Google Scholar 

  2. Barroso-Sousa R, Barry WT, Garrido-Castro AC, Hodi FS, Min L, Krop IE, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018;4(2):173–82.

    Article  Google Scholar 

  3. Funakoshi T, Shimada YJ. Risk of hypothyroidism in patients with cancer treated with sunitinib: a systematic review and meta-analysis. Acta Oncol. 2013;52(4):691–702.

    Article  CAS  Google Scholar 

Download references

Funding

No funding.

Author information

Authors and Affiliations

  1. Department of Health Sciences, University of Florence, viale Pieraccini, 6, 50139, Florence, Italy

    G. Roviello

  2. Department of Urology, University of Florence, Careggi Hospital, Florence, Italy

    D. Villari

  3. Department of Cell Systems and Anatomy, University of Texas Health San Antonio, San Antonio, TX, USA

    R. Roudi

Authors
  1. G. Roviello
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Villari
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Roudi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G. Roviello.

Ethics declarations

Conflict of interest

The other authors declare that there are no conflicts of interest with this work.

Ethical approval

This article does not contain any studies with human participant or animals performed by the author.

Informed consent

For this type of study formal consent is not required.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Roviello, G., Villari, D. & Roudi, R. Immunotherapy‑based combinations versus standard first‑line and hypothyroidism risk. Clin Transl Oncol 22, 1664–1665 (2020). https://doi.org/10.1007/s12094-020-02352-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-020-02352-4

Search

Navigation